ERBB2 and breast cancer: To determine the proper treatment strategy for patients with HR+HER2- breast cancer who had 1–2 suspicious ALNs on pretreatment breast magnetic resonance imaging (MRI), we explored the clinicopathologic factors related to multiple ALNs metastases in patients who underwent upfront surgery and axillary pCR in patients who received neoadjuvant chemotherapy.